PL3217980T3 - Cyklopiroks, cyklopiroksolamina lub prolek cyklopiroksu do zastosowania w leczeniu raka pęcherza - Google Patents

Cyklopiroks, cyklopiroksolamina lub prolek cyklopiroksu do zastosowania w leczeniu raka pęcherza

Info

Publication number
PL3217980T3
PL3217980T3 PL15859268.3T PL15859268T PL3217980T3 PL 3217980 T3 PL3217980 T3 PL 3217980T3 PL 15859268 T PL15859268 T PL 15859268T PL 3217980 T3 PL3217980 T3 PL 3217980T3
Authority
PL
Poland
Prior art keywords
ciclopirox
treatment
prodrug
bladder cancer
olamine
Prior art date
Application number
PL15859268.3T
Other languages
English (en)
Polish (pl)
Inventor
Scott J. Weir
Shrikant Anant
Original Assignee
The University Of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Kansas filed Critical The University Of Kansas
Publication of PL3217980T3 publication Critical patent/PL3217980T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL15859268.3T 2014-11-11 2015-11-10 Cyklopiroks, cyklopiroksolamina lub prolek cyklopiroksu do zastosowania w leczeniu raka pęcherza PL3217980T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462078069P 2014-11-11 2014-11-11
US201562134747P 2015-03-18 2015-03-18
PCT/US2015/059955 WO2016077346A1 (en) 2014-11-11 2015-11-10 Methods of bladder cancer treatment with ciclopirox, ciclopirox olamine, or a ciclopirox prodrug

Publications (1)

Publication Number Publication Date
PL3217980T3 true PL3217980T3 (pl) 2021-03-22

Family

ID=55954945

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15859268.3T PL3217980T3 (pl) 2014-11-11 2015-11-10 Cyklopiroks, cyklopiroksolamina lub prolek cyklopiroksu do zastosowania w leczeniu raka pęcherza

Country Status (12)

Country Link
US (1) US20170304329A1 (enExample)
EP (1) EP3217980B1 (enExample)
JP (1) JP2017533952A (enExample)
CN (2) CN116687941A (enExample)
DK (1) DK3217980T3 (enExample)
ES (1) ES2836208T3 (enExample)
HR (1) HRP20201893T1 (enExample)
HU (1) HUE052670T2 (enExample)
PL (1) PL3217980T3 (enExample)
PT (1) PT3217980T (enExample)
RS (1) RS61222B1 (enExample)
WO (1) WO2016077346A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11753379B2 (en) 2018-05-30 2023-09-12 Clariant International Ltd Process for forming 2-hydroxypyridine-1-oxide or derivatives thereof
CN113194945B (zh) * 2018-08-23 2024-07-23 佩勒梅德有限公司 环吡酮的抑制hbv核心组装的用途
WO2021078937A1 (en) * 2019-10-25 2021-04-29 Deutsches Krebsforschungszentrum Treatment of stat3 related diseases by iron chelators
EP4193989A1 (en) 2021-12-09 2023-06-14 Atlas Molecular Pharma, S.L. A formulation for an effective oral administration of ciclopirox with no adversal gasterointestinal toxicity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754965B2 (en) 1997-12-31 2002-11-28 University Of Kansas, The Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
AU2003251875A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
WO2010048712A1 (en) 2008-10-31 2010-05-06 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders
WO2011153197A1 (en) * 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
PL2646035T3 (pl) * 2010-12-02 2016-08-31 Univ Kansas Proleki 6-cykloheksylo-1-hydroksy-4-metylopirydyn-2(1h)-onu i ich pochodne

Also Published As

Publication number Publication date
DK3217980T3 (da) 2020-12-07
EP3217980A4 (en) 2018-05-02
RS61222B1 (sr) 2021-01-29
HRP20201893T1 (hr) 2021-02-05
ES2836208T3 (es) 2021-06-24
HUE052670T2 (hu) 2021-05-28
US20170304329A1 (en) 2017-10-26
WO2016077346A1 (en) 2016-05-19
CN107206012A (zh) 2017-09-26
JP2017533952A (ja) 2017-11-16
CN116687941A (zh) 2023-09-05
EP3217980B1 (en) 2020-10-14
EP3217980A1 (en) 2017-09-20
PT3217980T (pt) 2020-12-11